恩维达生物科学获得FDA批准，开展口服药物ENV-6946用于炎症性肠病（IBD）的一期临床试验。 Enveda Biosciences gets FDA go-ahead for Phase 1 trial of oral drug ENV-6946 for IBD.

Enveda生物科学已经获得林业发展局批准,开始对ENV-6946进行第一阶段临床试验,ENV-6946是一种用于煽动性肠道疾病(IBD)的口服小分子药物,这是它在临床发展方面的第三个候选者。 Enveda Biosciences has received FDA approval to begin a Phase 1 clinical trial for ENV-6946, an oral small molecule drug for inflammatory bowel disease (IBD), marking its third candidate in clinical development. 该药物源自自然化学,旨在解决未满足的免疫综合症治疗需要,包括坚持不力、反应不一和有效口服选择有限等。 The drug, derived from natural chemistry, aims to address unmet needs in IBD treatment, including poor adherence, variable responses, and limited effective oral options. 试验将评估该药物对IBD患者的安全和潜在功效。 The trial will evaluate the drug’s safety and potential efficacy in patients with IBD. 这个里程碑恰逢即将在波士顿举行的IBD峰会第四次精密医学会议, Enveda的IBD特许领导人将讨论治疗Crohn疾病和流行性科炎的挑战。 The milestone coincides with the upcoming 4th Precision Medicine in IBD Summit in Boston, where Enveda’s IBD franchise head will discuss challenges in treating Crohn’s disease and ulcerative colitis.